Search Orphan Drug Designations and Approvals
-
| Generic Name: | anthrax immune globulin (human) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | |||||||||||||||||
| Date Designated: | 07/29/2008 | ||||||||||||||||
| Orphan Designation: | Treatment of inhalational anthrax | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Cangene Corp. - Emergent Biosolutions 155 Innovation Drive R3T 5Y3 Winnipeg, MB Canada The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | anthrax immune globulin (human) |
|---|---|---|
| Trade Name: | ||
| Marketing Approval Date: | 03/24/2015 | |
| Approved Labeled Indication: | Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs | |
| Exclusivity End Date: | 03/24/2022 | |
| Exclusivity Protected Indication* : | Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







